Veterans

CHAP: COMMUNITY HEALTH ACCREDITATION PARTNER AWARDS MAXWELL HEALTHCARE ASSOCIATES’ nanaBEREAVEMENT PRODUCT ITS “CHAP VERIFIED” STATUS

SHOREVIEW, Minn., Feb. 19, 2025 /PRNewswire/ -- Maxwell Healthcare Associates (MHA) is pleased to announce that nanaBEREAVEMENT, a tech-enabled bereavement...

RAINFALL HEALTH ANNOUNCES INAUGURAL COMMITTEE WITH HEALTHCARE LEADERS IN AN UNPRECEDENTED MOVE TOWARD STANDARDIZING HEALTH CARE DELIVERY ACROSS THE COUNTRY

SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- The Advisory Committee provides strategic guidance to promote equitable and accessible healthcare. By...

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

error: Content is protected !!